Cargando…

Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment

BACKGROUND: Atypical subtrochanteric fracture and femoral fracture have been considered to be rare complications related to long-term bisphosphonates use. A reduced bone turnover rate may lead to delayed bone healing. Limited data have revealed that teriparatide treatment may reverse the effect of b...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeh, Wen-Ling, Su, Chun-Yi, Chang, Chia-Wei, Chen, Chien-Hao, Fu, Tsai-Sheng, Chen, Lih-Huei, Lin, Tung-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729282/
https://www.ncbi.nlm.nih.gov/pubmed/29237448
http://dx.doi.org/10.1186/s12891-017-1878-5
_version_ 1783286161198809088
author Yeh, Wen-Ling
Su, Chun-Yi
Chang, Chia-Wei
Chen, Chien-Hao
Fu, Tsai-Sheng
Chen, Lih-Huei
Lin, Tung-Yi
author_facet Yeh, Wen-Ling
Su, Chun-Yi
Chang, Chia-Wei
Chen, Chien-Hao
Fu, Tsai-Sheng
Chen, Lih-Huei
Lin, Tung-Yi
author_sort Yeh, Wen-Ling
collection PubMed
description BACKGROUND: Atypical subtrochanteric fracture and femoral fracture have been considered to be rare complications related to long-term bisphosphonates use. A reduced bone turnover rate may lead to delayed bone healing. Limited data have revealed that teriparatide treatment may reverse the effect of bisphosphonates and be effective in bone healing. METHODS: We reviewed patients with atypical subtrochanteric and femoral fracture related to bisphosphonates use between January 2008 and December 2014. Thirteen female patients were enrolled. Radiographic findings were compatible with the characteristics of atypical fracture. Surgical intervention was performed for all, and teriparatide use was advised postoperatively. Outcome measures included perioperative results, and clinical and radiographic outcome. RESULTS: Of the 13 female patients enrolled, 10 had subtrochanteric and 6 had proximal femoral fracture; 3 had bilateral fractures. The mean age of the patients at surgery was 70.15±6.36 years. Most fractures (68.8%) presented prodromal thigh pain. All patients were treated with an intramedullary fixation system without severe complications. The patients were divided into 2 groups based on whether they had received treatment with teriparatide or not. The mean time to bone union was 4.4 months in the teriparatide-treated group, and 6.2 months in the non-teriparatide-treated group (p=0.116). Six patients (75%) in the teriparatide-treated group and 4 (50%) in the non-teriparatide-treated group (p= 0.3) achieved bone union within 6 months. The means of the modified Harris Hip Score and Numerical Rating Scale were significantly better in the teriparatide-treated group at postoperative 6 months. Seven patients had the same ability to walk at the 1-year follow-up as they did before the atypical fracture. CONCLUSIONS: Teriparatide treatment in patients with atypical fracture may help in fracture healing, hip function recovery, and pain relief in this reduced bone turnover patient group.
format Online
Article
Text
id pubmed-5729282
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57292822017-12-18 Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment Yeh, Wen-Ling Su, Chun-Yi Chang, Chia-Wei Chen, Chien-Hao Fu, Tsai-Sheng Chen, Lih-Huei Lin, Tung-Yi BMC Musculoskelet Disord Research Article BACKGROUND: Atypical subtrochanteric fracture and femoral fracture have been considered to be rare complications related to long-term bisphosphonates use. A reduced bone turnover rate may lead to delayed bone healing. Limited data have revealed that teriparatide treatment may reverse the effect of bisphosphonates and be effective in bone healing. METHODS: We reviewed patients with atypical subtrochanteric and femoral fracture related to bisphosphonates use between January 2008 and December 2014. Thirteen female patients were enrolled. Radiographic findings were compatible with the characteristics of atypical fracture. Surgical intervention was performed for all, and teriparatide use was advised postoperatively. Outcome measures included perioperative results, and clinical and radiographic outcome. RESULTS: Of the 13 female patients enrolled, 10 had subtrochanteric and 6 had proximal femoral fracture; 3 had bilateral fractures. The mean age of the patients at surgery was 70.15±6.36 years. Most fractures (68.8%) presented prodromal thigh pain. All patients were treated with an intramedullary fixation system without severe complications. The patients were divided into 2 groups based on whether they had received treatment with teriparatide or not. The mean time to bone union was 4.4 months in the teriparatide-treated group, and 6.2 months in the non-teriparatide-treated group (p=0.116). Six patients (75%) in the teriparatide-treated group and 4 (50%) in the non-teriparatide-treated group (p= 0.3) achieved bone union within 6 months. The means of the modified Harris Hip Score and Numerical Rating Scale were significantly better in the teriparatide-treated group at postoperative 6 months. Seven patients had the same ability to walk at the 1-year follow-up as they did before the atypical fracture. CONCLUSIONS: Teriparatide treatment in patients with atypical fracture may help in fracture healing, hip function recovery, and pain relief in this reduced bone turnover patient group. BioMed Central 2017-12-13 /pmc/articles/PMC5729282/ /pubmed/29237448 http://dx.doi.org/10.1186/s12891-017-1878-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Yeh, Wen-Ling
Su, Chun-Yi
Chang, Chia-Wei
Chen, Chien-Hao
Fu, Tsai-Sheng
Chen, Lih-Huei
Lin, Tung-Yi
Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment
title Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment
title_full Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment
title_fullStr Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment
title_full_unstemmed Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment
title_short Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment
title_sort surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729282/
https://www.ncbi.nlm.nih.gov/pubmed/29237448
http://dx.doi.org/10.1186/s12891-017-1878-5
work_keys_str_mv AT yehwenling surgicaloutcomeofatypicalsubtrochantericandfemoralfracturerelatedtobisphosphonatesuseinosteoporoticpatientswithorwithoutteriparatidetreatment
AT suchunyi surgicaloutcomeofatypicalsubtrochantericandfemoralfracturerelatedtobisphosphonatesuseinosteoporoticpatientswithorwithoutteriparatidetreatment
AT changchiawei surgicaloutcomeofatypicalsubtrochantericandfemoralfracturerelatedtobisphosphonatesuseinosteoporoticpatientswithorwithoutteriparatidetreatment
AT chenchienhao surgicaloutcomeofatypicalsubtrochantericandfemoralfracturerelatedtobisphosphonatesuseinosteoporoticpatientswithorwithoutteriparatidetreatment
AT futsaisheng surgicaloutcomeofatypicalsubtrochantericandfemoralfracturerelatedtobisphosphonatesuseinosteoporoticpatientswithorwithoutteriparatidetreatment
AT chenlihhuei surgicaloutcomeofatypicalsubtrochantericandfemoralfracturerelatedtobisphosphonatesuseinosteoporoticpatientswithorwithoutteriparatidetreatment
AT lintungyi surgicaloutcomeofatypicalsubtrochantericandfemoralfracturerelatedtobisphosphonatesuseinosteoporoticpatientswithorwithoutteriparatidetreatment